Related references
Note: Only part of the references are listed.Downstaging in Pancreatic Cancer: A Matched Analysis of Patients Resected Following Systemic Treatment of Initially Locally Unresectable Disease
K. A. Bickenbach et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
Management of Patients with Pancreatic Adenocarcinoma: National Trends in Patient Selection, Operative Management, and Use of Adjuvant Therapy
Skye C. Mayo et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2012)
Fluorouracil-based Chemoradiation with Either Gemcitabine or Fluorouracil Chemotherapy after Resection of Pancreatic Adenocarcinoma: 5-Year Analysis of the US Intergroup/RTOG 9704 Phase III Trial
William F. Regine et al.
ANNALS OF SURGICAL ONCOLOGY (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Challenges in the Study of Adjuvant Chemoradiation After Pancreaticoduodenectomy
Christopher H. Crane et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Adjuvant Chemoradiation for Pancreatic Adenocarcinoma: The Johns Hopkins Hospital-Mayo Clinic Collaborative Study
Charles C. Hsu et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Progress for Resectable Cancer? A Population-Based Assessment of US Practices
Jessica P. Simons et al.
CANCER (2010)
A National Propensity-Adjusted Analysis of Adjuvant Radiotherapy in the Treatment of Resected Pancreatic Adenocarcinoma
Theodore P. McDade et al.
CANCER (2010)
Randomized Phase II Study of Gemcitabine Plus Radiotherapy Versus Gemcitabine, 5-Fluorouracil, and Cisplatin Followed by Radiotherapy and 5-Fluorouracil for Patients With Locally Advanced, Potentially Resectable Pancreatic Adenocarcinoma
Jerome Landry et al.
JOURNAL OF SURGICAL ONCOLOGY (2010)
Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review
R. Le Scodan et al.
ANNALS OF ONCOLOGY (2009)
Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and-3(v1) trials
J. P. Neoptolemos et al.
BRITISH JOURNAL OF CANCER (2009)
Improved survival with adjuvant external-beam radiation therapy in lymph node-negative pancreatic cancer - A united states population-based assessment
Avo Artinyan et al.
CANCER (2008)
Radiation therapy is associated with improved survival in patients with pancreatic adenocarcinoma: Results of a study from the surveillance, epidemiology, and end results (SEER) registry data
Lisa Hazard et al.
CANCER (2007)
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer - A Randomized controlled trial
Helmut Oettle et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer
JP Neoptolemos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Prognostic factors following curative resection for pancreatic adenocarcinoma - A population-based, linked database analysis of 396 patients
JE Lim et al.
ANNALS OF SURGERY (2003)
Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer:: a randomised controlled trial
JP Neoptolemos et al.
LANCET (2001)
Share Paper
